Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several risks and challenges, including regulatory delays, financial constraints, and clinical trial uncertainties. Despite positive preclinical data and cost-saving measures, the company's limited cash balance and operational risks overshadow potential benefits. The Q&A section revealed management's hesitance to provide clear guidance on trial timelines and efficacy, further dampening investor sentiment. The decision to halt the India trial due to regulatory issues adds to the negative outlook. Overall, these factors suggest a negative stock price reaction in the short term.
Key Financial Performance
Cash Balance $3.8 million as of June 30, 2025.
Consolidated Operating Expenses $1.8 million for the 3 months ended June 30, 2025, down $800,000 or 32% year-over-year from $2.6 million. The decrease was due to payroll-related savings, lower headcount, reduced stock-based compensation, lower legal fees, and reduced scientific consulting costs.
Operating Loss $1.8 million for the 3 months ended June 30, 2025, compared to $2.6 million in the prior year, reflecting a reduction of $800,000 due to cost efficiencies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Hemopurifier: Advanced lead oncology indication clinical program, completed first cohort treatments in Australian trial, and received DSMB recommendation to proceed to second cohort. Focused on safety and efficacy in removing extracellular vesicles to improve anti-PD-1 therapy response.
Long COVID Research: Presented preclinical data showing Hemopurifier's ability to remove extracellular vesicles implicated in long COVID. Collaborated with UCSF for blood sample analysis and demonstrated potential for addressing unmet medical needs in long COVID.
Australian Oncology Trial: Progressing with clinical trials in Australia, focusing on solid tumors resistant to immunotherapy. Decision to prioritize Australian trial over Indian trial to expedite regulatory approval and strategic partnerships.
Cost Reduction: Reduced operating expenses by 32% year-over-year, saving $800,000 through lower payroll, legal fees, and consulting costs.
Financial Position: Cash balance of $3.8 million as of June 30, 2025, with operating loss reduced to $1.8 million from $2.6 million in the prior year.
Focus Shift: Discontinued Indian oncology trial to concentrate resources on Australian trial, saving $500,000 to $1 million and accelerating progress towards regulatory milestones.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Delays: The decision to not proceed with the India study due to extended timelines and strategic priorities highlights potential delays in regulatory approvals and trial completions, which could impact the company's ability to meet milestones.
Financial Constraints: The company has a cash balance of $3.8 million as of June 30, 2025, and is actively reducing operating expenses. However, limited financial resources could constrain future R&D and clinical trial activities.
Clinical Trial Risks: The Australian oncology trial is still in early stages, with safety as the primary endpoint. The death of a patient in the first cohort and the need for further data analysis pose risks to the trial's success and timeline.
Market and Competitive Risks: The Hemopurifier targets a niche market with high unmet needs, but only 30%-40% of patients respond to current therapies. Competitive pressures and the need to demonstrate clear efficacy could impact market adoption.
Operational Risks: The company is focusing resources on the Australian trial, but any delays or complications in patient recruitment, data analysis, or regulatory approvals could hinder progress.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Australian Oncology Trial: The company expects to complete treatments by late 2025 or early 2026, analyze data, and be in a position to apply for a PMA or efficacy trial in Australia and engage strategic partners.
India Oncology Trial: The company decided not to proceed with the India study to focus resources on the Australian trial, conserving $500,000 to $1 million and avoiding potential delays in regulatory approval.
Long COVID Research: The company is exploring the use of its Hemopurifier for long COVID treatment, with preclinical data showing potential for removing extracellular vesicles implicated in the disease. Future collaborations and next steps are under discussion.
Platelet-Derived Extracellular Vesicles (PD-EVs): Preclinical studies show the Hemopurifier can remove 98.5% of PD-EVs, which are implicated in various diseases including cancer, lupus, and long COVID. This supports ongoing oncology trials and potential new applications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the primary endpoint of the study in Australia, and is the study on track to meet it?
A:The primary endpoint of the study in Australia is safety. The first cohort has been treated, and there are no adverse events related to the Hemopurifier treatment. The study is on track to meet the primary endpoint.
Q:How does the preclinical data of 98.5% extracellular vesicle removal compare to expectations for the clinical study?
A:The preclinical data of 98.5% extracellular vesicle removal in a laboratory setting is not expected to directly translate to the clinical study. The focus is on the actual reduction in patients treated, and data from the first cohort will provide insights.
Q:Why was the decision made to not move forward with the trial in India, and what are the implications for funding?
A:The decision to not move forward with the trial in India was primarily due to potential delays in approval and bureaucratic challenges, not cost savings. The company will need to raise more funds in the future, potentially with strategic partners rather than financial investors.
Q:What are the benefits of conducting clinical research in Australia compared to India?
A:Australia offers a 43% cash tax rebate for clinical research, which is not available in India. While hospital costs in India might be lower, the rebate in Australia could make it more cost-effective overall.
Q:Why was a parallel Indian trial initially set up alongside the Australian trial?
A:The Indian trial was initially set up because previous viral trials in India were initiated quickly and efficiently. However, new regulations and increased bureaucracy in India have slowed the process, making it less favorable.
Q:What efforts are being made to speed up enrollment in the Australian trial?
A:Efforts include accelerating timelines for data analysis, prescreening logs at active sites, recruiting additional sites, and using clinical trial liaisons and social media campaigns to boost enrollment.
Q:Will the company release data from the first cohort before completing all three cohorts?
A:The company may make some observations from the first cohort, but the full dose-response and treatment effects will only be clear after all three cohorts are completed. Observations from the first cohort are expected to be shared in September.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the exact timing or specifics of when efficacy data from the first cohort would be released, emphasizing that full conclusions require data from all three cohorts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aethlon Medical
COVID infection
COVID removal
Conference
DSMB
Fe New
Frakes Chief
GNA
Keystone Symposium
New Mexico
RD
Santa Fe
affinity resin
agent treatment
cohort patient
cohort sample
evening
hour treatment
indication
lectin
level
mind
oncology trial
participant
partner
patient COVID
patient cohort
patient treatment
platelet
point
poster
publication
removal vesicle
sclerosis
treatment patient
AEMD Transcript
Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript
Neutral6-10
Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript
Unknown2-12
The earnings call indicates mixed signals. The basic financial performance shows increased revenue but also higher operating losses, resulting in a neutral sentiment. The product development updates, particularly the progression to Cohort 2 in the oncology trial and the potential integration with the SLAMB system, are promising but face regulatory hurdles. Market strategy and expenses reflect positive cost management, though uncertainties remain. The Q&A reveals cautious optimism but lacks concrete data on treatment efficacy, leading to a neutral sentiment overall. Without market cap data, the prediction remains neutral.
Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript
Unknown11-12
The earnings call reveals several concerns: limited cash balance raising sustainability doubts, a decision to not proceed with the India trial, and challenges in patient recruitment. Despite reduced expenses, the financial health is precarious. The Q&A section highlights uncertainties in trial outcomes and management's evasive responses, which further dampen sentiment. The combination of these factors suggests a negative outlook for the stock price.
Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript
Unknown8-13
The earnings call highlights several risks and challenges, including regulatory delays, financial constraints, and clinical trial uncertainties. Despite positive preclinical data and cost-saving measures, the company's limited cash balance and operational risks overshadow potential benefits. The Q&A section revealed management's hesitance to provide clear guidance on trial timelines and efficacy, further dampening investor sentiment. The decision to halt the India trial due to regulatory issues adds to the negative outlook. Overall, these factors suggest a negative stock price reaction in the short term.
AEMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
